ReviewMedical2026

Lipid-based nanoencapsulation prolongs the antinociceptive effect of cannabidiol in experimental neuropathic pain.

Monteiro Santana T.; Oliveira Cruz A.; da Silva Oliveira L.; Lauria P.; Brustolim D.; Tabosa do Egito E.; Viana M.; Villarreal C. · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2026

Research summary

**Background & Methods** This experimental study investigated whether lipid-based microemulsion encapsulation (LS-CBD) could improve cannabidiol's therapeutic profile in neuropathic pain. Male C57BL/6 mice with partial sciatic nerve ligation received oral administration of free CBD or LS-CBD at doses of 25, 50, and 75 mg/kg, with assessments of mechanical and thermal nociception following acute and seven-day repeated dosing. **Key Findings** • LS-CBD demonstrated superior pharmacokinetic properties compared to free CBD, prolonging thermal antinociceptive duration from 2 hours to 1-8 hours while maintaining comparable peak antinociceptive magnitude (50.0% vs. 53.2%), indicating extended drug action rather than increased potency. • During repeated administration, LS-CBD produced sustained mechanical antinociceptive activity throughout the seven-day treatment period, while both formulations demonstrated comparable and sustained thermal antinociception without tolerance development. • Molecular analysis revealed both CBD and LS-CBD upregulated antioxidant transcripts (Sod1, Cat) and downregulated neuroinflammatory markers (Nos2, Gfap) in dorsal root ganglia, suggesting mechanism of action involves attenuating nitrosative stress and satellite glial cell activation. **Dosage & Administration** Oral doses of 25, 50, and 75 mg/kg administered acutely and repeatedly over seven days in murine model. **Safety & Adverse Effects** Neither CBD nor LS-CBD induced hematological abnormalities, biochemical alterations, or body weight changes following repeated administration. No adverse effects were reported in this study. **Evidence Quality** This preclinical study represents a proof-of-concept investigation with significant limitations regarding translational applicability. The research was conducted exclusively in a murine neuropathic pain model, limiting generalizability to human neuropathic pain conditions. The study employed behavioral pain assessment and molecular analysis in isolated tissue, which may not fully reflect systemic pharmacodynamics. The lipid-based formulation demonstrated high entrapment efficiency (96.8%) and physicochemical stability, supporting the nanoencapsulation strategy; however, human clinical trials are required to establish efficacy, optimal dosing, and safety profiles. As an experimental animal study published in 2026, this represents emerging evidence suggesting lipid-based nanoencapsulation as a promising delivery strategy to extend CBD's antinociceptive duration in neuropathic pain management.

Summary generated by DeepWeed from the published abstract. See the original paper for full methods and results.

Journal
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Year
2026
Study type
Review
Read the original paper (DOI) ↗
Ask how this study fits the wider evidence — across 26,000+ papers.
Ask DeepWeed

More recent cannabis research

This page summarises published research for informational purposes only — it isn't medical advice. Always refer to the original publication for full methods, results and limitations.

← Back to home